TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02164552

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D3 pills
Description: Dietary supplement

Intervention type: OTHER
Intervention: Placebo pills
Description: Placebo pills similar in appearance and shape but without vitamin D
Study: NCT00043693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Intervention for Dual Diagnosis
Description: The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family psychoeducation program
Description: The family psychoeducation program consists of 6 weekly sessions.
Study: NCT03044197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/ultrasound transperineal prostate biopsy
Description: 3-6 targeted biopsy cores from each prostate region of interest

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transrectal ultrasound-guided prostate biopsy
Description: 12 systematic biopsy cores
Study: NCT03657472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30061
Description: Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30061
Description: Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30061
Description: Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® 5/160mg & Lipitor® 20mg
Description: Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® 5/160mg & Lipitor® 20mg
Description: Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® 5/160mg & Lipitor® 20mg
Description: Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
Study: NCT01971346

Intervention type: DRUG
Group type: OTHER
Intervention: etanercept
Description: 100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
Study: NCT01971658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexaméthasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexaméthasone
Study: NCT02320890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YBand (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-YBand (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study: NCT05738200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Description: A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
Study: NCT01583465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamantys
Description: Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard electrocautery (Bovie)
Description: Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
Study: NCT04130555

Intervention type: DEVICE
Intervention: CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)
Description: Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
Study: NCT00758511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25% Sucrose
Description: orally administrated 25%Sucrose before, during and after heel stick

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facilitated tucking
Description: facilitated tucking before, during and after heel stick

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose and facilitated tucking
Description: orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
Study: NCT01639027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drotaverine
Description: 40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
Study: NCT01652716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly suspension
Description: Exenatide suspension 2 mg weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide twice daily
Description: 5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
Study: NCT01045304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT02942537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave treatment
Description: Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery embolization
Description: Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
Study: NCT02585193

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Watchers Intervention
Description: All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
Study: NCT00826878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951)
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated.
Study: NCT04205864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombi-Gel
Description: Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pelvic lymphadenectomy
Description: Conventional Pelvic lymphadenectomy
Study: NCT05259748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors
Description: Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
Study: NCT01035229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus Placebo
Description: Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
Study: NCT03818542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: intravenous infusion
Study: NCT01045304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01725568

Intervention type: DEVICE
Intervention: BioMonitor
Description: Implantable cardiac monitor
Study: NCT04187196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methohexital
Description: Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
Study: NCT04383821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Trunk Mask
Description: The DTM (oxygen delivery system) is worn by the patient for 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Rebreather mask
Description: The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
Study: NCT02972528

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Lysate
Description: Direct injection of allogenic Platelet Lysate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Poor Plasma
Description: Direct injection of allogenic Platelet Poor Plasma
Study: NCT01337297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
Study: NCT04294004

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TGplPTH1-34 in fibrin
Description: TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TGplPTH1-34 in fibrin
Description: TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Bone Graft
Description: Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
Study: NCT03781076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
Study: NCT00803127

Intervention type: DEVICE
Intervention: vs-sense
Description: detection swab
Study: NCT02755831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-natal care
Description: Standard Pre-Natal Care
Study: NCT02239536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hot snare polypectomy
Description: hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
Study: NCT03818542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: intratumoral injection
Study: NCT00988039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aluvia + 2NRTIs
Description: Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.
Study: NCT02239536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hot snare polypectomy after saline injection
Description: hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
Study: NCT00096044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Oral
Study: NCT03139916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide causes cell death and shrinks and kills the cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab may activate (cause) the immune system to attack the cancer cells

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation causes cell death and shrinks and kills the cancer cells.
Study: NCT01620580

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Information
Description: The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
Study: NCT01957475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product Y
Description: Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product Y
Description: Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product Z
Description: Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product Z
Description: Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
Study: NCT02467725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic culture platform
Description: Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
Study: NCT03407872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI
Description: Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI
Description: Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.
Study: NCT02977234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoamyl 2-Cyanoacrylate
Study: NCT03567863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®
Description: The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®
Description: The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
Study: NCT01420081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: 154mg IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: 154mg IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: 154mg IV weekly